Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, Myeloma23 May 2019
Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on accessAccess, MPE6 May 2019
Results of MPE members participation in EMA survey on bortezomibMPE, Myeloma, Patient evidence3 May 2019
MPE will hold a webinar on ASH 2018 highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma16 January 2019
Daratumumab increases progression-free survival in newly diagnosed myeloma patients ineligible for transplantMyeloma5 December 2018
